4.4 Article

Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC

Journal

BMJ OPEN DIABETES RESEARCH & CARE
Volume 10, Issue 1, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjdrc-2021-002667

Keywords

glycated hemoglobin A; kidney; oxidative stress; diabetic neuropathies

Funding

  1. NIDDK/NIH [1DP3DK101123]
  2. Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease [U01 DK094176, U01 DK094157]
  3. National Eye Institute
  4. National Institute of Neurologic Disorders and Stroke
  5. General Clinical Research Centers Program [1993-2007]
  6. Clinical Translational Science Center Program (2006-present)
  7. Bethesda, Maryland, USA
  8. Abbott Diabetes Care (Alameda, California)
  9. Animas (Westchester, Pennsylvania)
  10. Bayer Diabetes Care (North America Headquarters, Tarrytown, New York)
  11. Becton
  12. Company (Franklin Lakes, New Jersey)
  13. Eli Lilly (Indianapolis, Indiana)
  14. Extend Nutrition (St. Louis, Missouri)
  15. Insulet Corporation (Bedford, Massachusetts)
  16. Lifescan (Milpitas, California)
  17. Medtronic Diabetes (Minneapolis, Minnesota)
  18. Nipro Home Diagnostics (Ft. Lauderdale, Florida)
  19. Nova Diabetes Care (Billerica, Massachusetts)
  20. Omron (Shelton, Connecticut)
  21. Perrigo Diabetes Care (Allegan, Michigan)
  22. Roche Diabetes Care (Indianapolis, Indiana)
  23. SanofiAventis (Bridgewater, New Jersey)

Ask authors/readers for more resources

This study assessed the impact of glycemic control on pAGEs and their association with subsequent microvascular disease. The results showed that certain pAGEs decreased with intensive glycemic control and were correlated with HbA1c. These pAGEs were also associated with the risk of various microvascular complications in patients with diabetes, and the association with diabetic kidney disease remained significant even after adjustment for HbA1c.
Introduction To assess impact of glycemic control on plasma protein-bound advanced glycation end products (pAGEs) and their association with subsequent microvascular disease. Research design and methods Eleven pAGEs were measured by liquid chromatography-mass spectrometry in banked plasma from 466 participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study at three time points (TPs): DCCT year 4 (TP1) and year 8 (TP2) and EDIC year 5/6 (TP3). Correlation coefficients assessed cross-sectional associations, and Cox proportional hazards models assessed associations with subsequent risk of microvascular complications through EDIC year 24. Results Glucose-derived glycation products fructose-lysine (FL), glucosepane (GSPN) and carboxymethyl-lysine (CML) decreased with intensive glycemic control at both TP1 and TP2 (p<0.0001) but were similar at TP3, and correlated with hemoglobin A1c (HbA1c). At TP1, the markers were associated with the subsequent risk of several microvascular outcomes. These associations did not remain significant after adjustment for HbA1c, except methionine sulfoxide (MetSOX), which remained associated with diabetic kidney disease. In unadjusted models using all 3 TPs, glucose-derived pAGEs were associated with subsequent risk of proliferative diabetic retinopathy (PDR, p<0.003), clinically significant macular edema (CSME, p<0.015) and confirmed clinical neuropathy (CCN, p<0.018, except CML, not significant (NS)). Adjusted for age, sex, body mass index, diabetes duration and mean updated HbA1c, the associations remained significant for PDR (FL: p<0.002, GSPN: p=0.02, CML: p<0.003, pentosidine: p<0.02), CMSE (CML: p<0.03), albuminuria (FL: p<0.02, CML: p<0.03) and CCN (FL: p<0.005, GSPN : p<0.003). Conclusions pAGEs at TP1 are not superior to HbA1c for risk prediction, but glucose-derived pAGEs at three TPs and MetSOX remain robustly associated with progression of microvascular complications in type 1 diabetes even after adjustment for HbA1c and other factors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available